Anuh Pharma Limited (BOM:506260)
India · Delayed Price · Currency is INR 75.85
-0.41 (-0.54%)
At close: Aug 17, 2026
Anuh Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 7,790 | 7,717 | 6,615 | 6,470 | 5,275 | 4,866 | |
Revenue Growth | 9.70% | 16.65% | 2.24% | 22.66% | 8.39% | 12.66% |
Cost of Revenue | 6,043 | 6,086 | 5,067 | 4,914 | 4,075 | 3,809 |
Gross Profit | 1,747 | 1,631 | 1,548 | 1,556 | 1,200 | 1,057 |
Selling, General & Admin | 290.16 | 279.62 | 244.91 | 206.91 | 180.15 | 156.67 |
Other Operating Expenses | 720.31 | 674.35 | 655.21 | 594.25 | 486.85 | 417.13 |
Operating Expenses | 1,122 | 1,066 | 998.53 | 887.24 | 762.31 | 691.69 |
Operating Income | 625.39 | 564.6 | 549.51 | 668.73 | 437.21 | 365.35 |
Interest Expense | -2.65 | -4.72 | -6.19 | -3.54 | -2.18 | -9.61 |
Interest & Investment Income | 6.6 | 6.6 | 14.8 | 12.68 | 14.98 | 23.98 |
Currency Exchange Gain (Loss) | -61.22 | -61.22 | -27.81 | -2.86 | -21.46 | -16.49 |
Other Non Operating Income (Expenses) | -3.08 | 0.04 | 1.29 | 1.08 | 2.63 | 1.01 |
EBT Excluding Unusual Items | 565.04 | 505.29 | 531.59 | 676.1 | 431.17 | 364.24 |
Gain (Loss) on Sale of Investments | 35.98 | 35.98 | 78.3 | 107.21 | 43.39 | 26.37 |
Gain (Loss) on Sale of Assets | 0.94 | 0.94 | 0.17 | -0.22 | 0.15 | 0.62 |
Pretax Income | 601.96 | 542.21 | 610.05 | 783.1 | 474.7 | 391.22 |
Income Tax Expense | 160.27 | 131.75 | 136.53 | 182.52 | 112.91 | 85.61 |
Net Income | 441.7 | 410.46 | 473.52 | 600.58 | 361.8 | 305.61 |
Net Income to Common | 441.7 | 410.46 | 473.52 | 600.58 | 361.8 | 305.61 |
Net Income Growth | -4.28% | -13.32% | -21.16% | 66.00% | 18.38% | 7.47% |
Shares Outstanding (Basic) | 100 | 100 | 50 | 100 | 100 | 100 |
Shares Outstanding (Diluted) | 100 | 100 | 50 | 100 | 100 | 100 |
Shares Change | 0.07% | 100.00% | -50.00% | - | - | - |
EPS (Basic) | 4.40 | 4.10 | 9.45 | 5.99 | 3.61 | 3.05 |
EPS (Diluted) | 4.40 | 4.10 | 9.45 | 5.99 | 3.61 | 3.05 |
EPS Growth | -4.35% | -56.66% | 57.69% | 66.00% | 18.38% | 7.47% |
Free Cash Flow | - | -108.8 | 169.79 | 79.09 | 523.52 | 272.49 |
Free Cash Flow Per Share | - | -1.09 | 3.39 | 0.79 | 5.22 | 2.72 |
Dividend Per Share | - | 1.500 | 1.500 | 1.250 | 1.000 | 0.875 |
Dividend Growth | - | 0% | 20.00% | 25.00% | 14.29% | 16.67% |
Gross Margin | 22.43% | 21.13% | 23.40% | 24.05% | 22.74% | 21.72% |
Operating Margin | 8.03% | 7.32% | 8.31% | 10.34% | 8.29% | 7.51% |
Profit Margin | 5.67% | 5.32% | 7.16% | 9.28% | 6.86% | 6.28% |
Free Cash Flow Margin | - | -1.41% | 2.57% | 1.22% | 9.93% | 5.60% |
EBITDA | 740.56 | 673.19 | 631.74 | 749.41 | 531.16 | 481.55 |
EBITDA Margin | 9.51% | 8.72% | 9.55% | 11.58% | 10.07% | 9.89% |
D&A For EBITDA | 115.17 | 108.58 | 82.23 | 80.68 | 93.95 | 116.2 |
EBIT | 625.39 | 564.6 | 549.51 | 668.73 | 437.21 | 365.35 |
EBIT Margin | 8.03% | 7.32% | 8.31% | 10.34% | 8.29% | 7.51% |
Effective Tax Rate | 26.62% | 24.30% | 22.38% | 23.31% | 23.79% | 21.88% |
Revenue as Reported | 7,830 | 7,760 | 6,710 | 6,591 | 5,336 | 4,918 |
Advertising Expenses | - | 9.14 | 8.05 | 7.37 | 3.17 | 0.18 |